| Hythiam, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20090215751 | Use of Selective Chloride Channel Modulators to Treat Alcohol and/or Stimulant Substance Abuse - The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABA | 08-27-2009 |
| 20080280885 | Methods for Treating Anxiety Related Disorders - The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, methods of, and compositions for, modulating the expression of certain GABAA receptor subunits are used to treat anxiety-related disorders and depressive disorders associated with physiological tolerance to endogenous neurosteroids. | 11-13-2008 |
| 20080255097 | Methods for the Treatment of Substance Abuse and Dependence - The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. More specifically, the present invention relates to methods of and compositions for treating and relieving symptoms associated with substance abuse and withdrawal. The present invention relates to methods of and compositions for treating and relieving symptoms associated with addiction to antidepressants, opiates, nicotine or marijuana. In one method, a patient is treated with a composition that directly or indirectly modulates GABA | 10-16-2008 |
| 20080207601 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence - Compositions for reducing dependency and addiction to substances of abuse are provided. Chloride channels such as the GABA | 08-28-2008 |
| 20080207599 | Use of Selective Chloride Channel Modulators to Treat Methamphetamine Abuse - The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABA | 08-28-2008 |
